Lobectomy for NSCLC by VATS Versus Thoracotomy
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03786003|
Recruitment Status : Not yet recruiting
First Posted : December 24, 2018
Last Update Posted : May 8, 2019
|Condition or disease||Intervention/treatment||Phase|
|Carcinoma, Non-Small-Cell Lung||Procedure: VATS Procedure: Thoracotomy||Not Applicable|
It is a randomized clinical trial comparing VATS with thoracotomy for consolidation-predominant early stage NSCLC. The primary objective of this study is to determine VATS is non-inferior to thoracotomy with respect to DFS.
To our opinion, NSCLC at very early stages could not objectively reflect the long-term advantage of VATS, while VATS is not a reasonable choice for late NSCLC. As a result, we design this trial by recruiting patients whose stage is cT1N0-1M0 and the lesion is consolidation-predominant. To determine the clinical stages, CT scan would be performed and PET-CT/EBUS-TBNA/mediastinoscopy would be conducted for those who are suspected to have mediastinum lymph node metastases or distant metastases. The detailed inclusion criteria includes tumor ≤ 3cm; Mediastinum lymph nodes diameter ≤ 1 cm on computed tomography (CT) scan, or a PET scan showing no uptake / a negative mediastinoscopy / a negative " EBUS-TBNA " following mediastinal lymph nodes diameter ＞ 1 cm on CT scan; No distant metastasis; Solid tumor that C/T ratio =1, or part-solid tumor that 0.5 ≤ C/T ratio < 1 and diameter ≥ 1.5cm on CT scan. Specially, the lymph node whose diameter is larger than 1 centimeter in the lung field is considered as stage N1.
In previous statistics of our center, the 5-year DFS of this subgroup patients by performing thoracotomy was 77.52%. If the 5-year DFS does not differ by more than 7%, the two arms will be regarded to be equivalent. Calculated by PASS software, the sample size of patients to be enrolled in the two arms is estimated as 948 cases. The benign cases diagnosed after operation would not be included in analysis according to modified intention-to-treat principle. Considering a 10% benign diseases may be diagnosed, the sample size is adjusted to 1053 cases and the number of event (relapse or death due to tumor) is estimated to be 251 cases.
Patients were divided into two groups by the random table method. The random table has been generated by PASS software with Efron's Biased Coin (p = 0.67) algorithm. 527 cases have been allocated into either group.
The lobectomy and mediastinal lymph node dissection by VATS or thoracotomy would be conducted by standard procedure. Each participating doctor would be evaluated by the trial management committee to ensure proper surgical technique. If the VATS were transferred to thoracotomy, the cause would be recorded and the prognosis result would be still analyzed as the VATS group. Patients would be follow-up by every 6 months after surgery and examination would be conducted routinely.
The interim analysis is set at 5-year after the trial begin and at the timing that 50% events occurred (126 events). If either side of the two arms is determined superior to the other side and the imbalance was confirmed after evaluation, the study would be permanently closed to new patient enrollment and a primary outcome would be published. The follow-up of recruited patients would continue according to the study protocol.
The final analysis would be performed as the follow-up period reach 5 years. The main outcome is DFS at 5 years post surgery. The secondary outcome measures include OS at 5 years post surgery, degree of pain evaluated by NRS and rate of patients with perioperative complication.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||1053 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Lobectomy for Consolidation-predominant Early Stage NSCLC by VATS Versus Thoracotomy|
|Estimated Study Start Date :||June 1, 2019|
|Estimated Primary Completion Date :||June 1, 2024|
|Estimated Study Completion Date :||June 1, 2029|
Video-assisted thoracoscopic surgery
Standard video assisted thoracic surgery, no use of rib-spreader.
Active Comparator: Thoracotomy
- Disease-free survival [ Time Frame: Five years after the surgery ]Disease-free survival means the period after surgery when no disease can be detected.
- Overall survival [ Time Frame: Five years after the surgery ]Overall survival means the period after surgery when a patient doesn't die directly from that disease or from an unrelated cause.
- Degree of pain evaluated by NRS (Numeric rating scale) [ Time Frame: The two days after surgery and the four weeks after discharge ]The Numeric Rating Scale (NRS-11) is an 11-point scale for patient self-reporting of pain. It is for adults and children 10 years old or older. 0 point represents no Pain. 1-3 point represents mild pain (nagging, annoying, interfering little with ADLs (activities of daily living)). 4-6 point represents moderate Pain (interferes significantly with ADLs). 7-10 point represents severe Pain (disabling; unable to perform ADLs). The degree of postoperative chest pain would be recorded at 2 days after surgery by a doctor and 4 weeks after discharge by a phone inquiry.
- Rate of patients with perioperative complication [ Time Frame: The one month after surgery ]The perioperative complication includes wound infection, hemorrhage, infection, pleural effusion, pneumothorax, cardiovascular problem and etc within a month after surgery.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03786003
|Contact: Haoxuan Wu, M.D.||firstname.lastname@example.org|
|Contact: Haiquan Chen, Ph.D|
|Principal Investigator:||Shanghai Cancer Center Chen, Ph.D||Shanghai Cancer Center|